Cormorant Asset Management holds 5.95% of Cabaletta Bio
Cormorant Asset Management, LP and Bihua Chen report a 5.95% beneficial stake in Cabaletta Bio, Inc. The filing covers common stock, including shares issuable from warrants.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cormorant Asset Management, LP and Bihua Chen report a 5.95% beneficial stake in Cabaletta Bio, Inc. The filing covers common stock, including shares issuable from warrants. They beneficially own 10,000,000 shares of common stock, based on Cabaletta Bio’s reported 163,054,796 shares outstanding as of May 7, 2026.
The 10,000,000-share position consists of 5,000,000 common shares and warrants to purchase an additional 5,000,000 shares. Both Cormorant Asset Management and Bihua Chen report shared voting and dispositive power over all 10,000,000 shares, with no sole voting or dispositive power. The economic rights to dividends and sale proceeds reside with the Cormorant Funds, including Cormorant Global Healthcare Master Fund, LP, which may receive dividends or proceeds relating to more than 5% of the class.
Key Figures
Key Terms
beneficial owner financial
dispositive power financial
warrants financial
percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Cabaletta Bio (CABA) does Cormorant Asset Management report owning?
What role do warrants play in Cormorant’s Cabaletta Bio (CABA) position?
Which Cormorant fund holds more than 5% of Cabaletta Bio (CABA)?
On whose behalf is the Cabaletta Bio (CABA) stake reported in this ownership filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.